RCUS Arcus Biosciences Inc.

+0.05  (+1%)
Previous Close 9.64
Open 9.66
Price To Book 1.95
Market Cap 431544489
Shares 44,535,035
Volume 80,974
Short Ratio 9.87
Av. Daily Volume 99,078

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 dose-expansion cohort to be initiated mid-2019.
Healthy volunteers
Phase 1 data due mid-2019.
AB928 + Doxil
Triple negative breast cancer (TNBC) and ovarian cancer
Phase 1 initial safety, PK/PD profile, biomarker analysis from the dose-escalation portion due 2Q 2019.
Colorectal Cancer
Phase 1 initial data due at ASCO June 1, 2019, 8am.
AB928 + AB122
Solid tumors
Phase 1 initial data due 2H 2019.
AB154 + AB122
Solid tumors
Phase 1 safety data due 2H 2019.
Health volunteers

Latest News

  1. Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
  2. Is Arcus Biosciences, Inc. (RCUS) A Good Stock To Buy?
  3. Infinity (INFI) Earnings and Sales Miss Estimates in Q1
  4. Trade Anxieties Return with a Vengeance
  5. Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates
  6. Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer
  7. Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122
  8. Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?
  9. Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
  10. What Kind Of Shareholders Own Arcus Biosciences, Inc. (NYSE:RCUS)?
  11. Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue?
  12. Arcus Biosciences Appoints Rekha Hemrajani as Chief Operating and Financial Officer
  13. Infinity Inks Deal With Roche for Phase II Study of IPI-549
  14. Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates
  15. Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting
  16. Arcus Biosciences Announces Participation at Upcoming Investor Conference
  17. Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today
  18. Arcus Biosciences Announces Transition of Chief Financial and Operating Officer
  19. Here are the winners and losers from Bay Area's IPO class of 2018
  20. This year's Bay Area IPO batch remains up 44% despite market turbulence